Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors
- PMID: 30557385
- PMCID: PMC6296549
- DOI: 10.1371/journal.pone.0209250
Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors
Abstract
Rivastigmine (Riv) is a potent and selective cholinesterase (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) inhibitor developed for the treatment of Alzheimer's disease (AD). To elucidate whether Riv causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. At concentrations of 0-100 μM, Riv was non-toxic in PC12 cells. Riv caused dose-dependent (10-100 μM) enhancement of NGF-induced neurite outgrowth, which was completely inhibited by the TrkA antagonist GW-441756. By contrast, Riv-mediated enhancement of neurite outgrowth was not blocked by the acetylcholine receptor antagonists, scopolamine and hexamethonium. However, the sigma-1 receptor (Sig-1R) antagonist NE-100 and sigma-2 receptor (Sig-2R) antagonist SM-21 each blocked about half of the Riv-mediated enhancement of NGF-induced neurite outgrowth. Interestingly, the simultaneous application of NE-100 and SM-21 completely blocked the enhancement of NGF-induced neurite outgrowth by Riv. These findings suggest that both Sig-1R and Sig-2R play important roles in NGF-induced neurite outgrowth through TrkA and that Riv may contribute to neuronal repair via Sig-1R and Sig-2R in AD therapy.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures









Similar articles
-
Effects of fluvoxamine on nerve growth factor-induced neurite outgrowth inhibition by dexamethasone in PC12 cells.Biosci Biotechnol Biochem. 2019 Apr;83(4):659-665. doi: 10.1080/09168451.2018.1553607. Epub 2018 Dec 13. Biosci Biotechnol Biochem. 2019. PMID: 30543144
-
Sertraline inhibits nerve growth factor-induced neurite outgrowth in PC12 cells via a mechanism involving the sigma-1 receptor.Eur J Pharmacol. 2019 Jun 15;853:129-135. doi: 10.1016/j.ejphar.2019.03.032. Epub 2019 Mar 19. Eur J Pharmacol. 2019. PMID: 30902656
-
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors.Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1656-9. doi: 10.1016/j.pnpbp.2008.06.011. Epub 2008 Jul 2. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18647636
-
[Development of New Neurotrophic Compounds Based on Talaumidin].Yakugaku Zasshi. 2020;140(2):129-137. doi: 10.1248/yakushi.19-00167. Yakugaku Zasshi. 2020. PMID: 32009033 Review. Japanese.
-
The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's.Expert Opin Ther Targets. 2021 May;25(5):401-414. doi: 10.1080/14728222.2021.1939681. Epub 2021 Jun 17. Expert Opin Ther Targets. 2021. PMID: 34110944 Review.
Cited by
-
Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases.Int J Mol Sci. 2023 Mar 26;24(7):6251. doi: 10.3390/ijms24076251. Int J Mol Sci. 2023. PMID: 37047224 Free PMC article. Review.
-
Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.Pharmaceutics. 2025 Jan 17;17(1):128. doi: 10.3390/pharmaceutics17010128. Pharmaceutics. 2025. PMID: 39861773 Free PMC article. Review.
-
Atypical Antipsychotic Drug Ziprasidone Protects against Rotenone-Induced Neurotoxicity: An In Vitro Study.Molecules. 2020 Sep 14;25(18):4206. doi: 10.3390/molecules25184206. Molecules. 2020. PMID: 32937854 Free PMC article.
-
Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.Neurochem Int. 2024 Dec;181:105883. doi: 10.1016/j.neuint.2024.105883. Epub 2024 Oct 18. Neurochem Int. 2024. PMID: 39427854 Review.
-
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.Pharmacol Res Perspect. 2020 Aug;8(4):e00622. doi: 10.1002/prp2.622. Pharmacol Res Perspect. 2020. PMID: 32691984 Free PMC article. Review.
References
-
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944. - PubMed
-
- Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741–766. 10.1152/physrev.2001.81.2.741 - DOI - PubMed
-
- Kasa P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer's disease. Prog Neurobiol 52: 511–535. - PubMed
-
- Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68: 209–245. - PubMed
-
- Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res 36: 375–399. 10.1007/s12272-013-0036-3 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials